

Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C5467745B606EN.html>

Date: December 2022

Pages: 99

Price: US\$ 2,000.00 (Single User License)

ID: C5467745B606EN

Abstracts

Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2022, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide

covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 15, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 3 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Cervical Intraepithelial Neoplasia (CIN) - Overview

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development

Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products

Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones

Featured News & Press Releases

Mar 08, 2022: Nykode Therapeutics to present at 2022 American Association for Cancer Research (AACR) Annual Meeting

Dec 14, 2021: INOVIO highlights key updates on phase 3 program for VGX-3100, its DNA-based immunotherapy for the treatment of cervical HSIL caused by HPV-16 and/or HPV-18

Apr 21, 2021: Antiva Biosciences appoints Clifford Samuel to Board of Directors

Mar 26, 2021: The VGX-3100 project of Dongfanglue passed the approval of the Genetics Office, and officially launched the domestic phase III clinical trial

Feb 20, 2020: Novan receives phase 2 NIH federal grant of approximately \$1.0 million

Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event

Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019

Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data

Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial

Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer

Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001

May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100

Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as 'Best Therapeutic Vaccine' at World Vaccine Congress

Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2022

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2022 (Contd..1)

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C5467745B606EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5467745B606EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

